We believe that analyzing legal precedents by reference to the stage of drug or device development at which the setback occurs may yield useful insights and assist in risk mitigation and insurance strategies.
In this webinar we will discuss:
- Overview and analysis of trends in decisions involving life sciences companies with products at two distinct stages of development—pre- and post-FDA approval and takeaways that can help guide disclosure approaches
- Recent cases and what those reveal about the events that can draw a lawsuit
- Insight into the D&O Insurance underwriters’ reaction to the volatile life science shareholder litigation landscape
Sara Brody, Partner, Sidley
Kristin Kraeger, Managing Director,
Financial Services Group, Aon